Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

To main content To sitemap To news Check availability details

Innovation environments for more accurate solutions in health

Since 2021, Vinnova has been funding eleven ambitious cross-border collaborations that contribute to more accurate solutions across the entire health sector and to strengthening Sweden as a life science nation. The innovation environments focus on, among other things, early detection of dementia, personalized use of antibiotics and better preparedness for future pandemics.

This web page has been machine translated. If there are any uncertainties, please refer to the Swedish text.

Så här går det till

  • in

    The goal of the PrecisionPrevent innovation environment is to dramatically change the care of a chronic disease, rheumatoid arthritis (RA), from today's long-term, often lifelong, expensive and complex treatment to prevention and early and potentially curative treatment.

    The goal of the PrecisionPrevent innovation environment is to dramatically change the care of a chronic disease, rheumatoid arthritis (RA), from today's long-term, often lifelong, expensive and complex treatment to prevention and early and potentially curative treatment.

    With today's knowledge about the development of RA, it is possible to identify individuals at high risk of disease and create prevention programs that can be adapted to the genetic, environmental, immunological and clinical factors responsible for the development of the disease. It is currently not possible for healthcare to identify and care for these people at high risk of RA and we will, with a combination of digital tools and multiplex serological and genetic diagnostics, work to establish this prevention program within healthcare.

    Coordinator: Karolinska Institutet (Per-Johan Jakobsson)

    Contact: Scientific coordinator: Martina.Johannesson@ki.se

    With today's knowledge about the development of RA, it is possible to identify individuals at high risk of disease and create prevention programs that can be adapted to the genetic, environmental, immunological and clinical factors responsible for the development of the disease. It is currently not possible for healthcare to identify and care for these people at high risk of RA and we will, with a combination of digital tools and multiplex serological and genetic diagnostics, work to establish this prevention program within healthcare.

    Coordinator: Karolinska Institutet (Per-Johan Jakobsson)

    Contact: Scientific coordinator: Martina.Johannesson@ki.se

  • in

    PNI's vision is that the consumer should be able to choose the healthiest food based on optimal adaptation to their own digestive system.

    PNI's vision is that the consumer should be able to choose the healthiest food based on optimal adaptation to their own digestive system.

    As objective and strategies for PNI are linked to those of PAN Sweden, there is a shared interest in applying a precision nutrition perspective to clarify the relationships between processing, structure, bioavailability, and digestion and fermentation of proteins with health effects in the form of intestinal, metabolic, and mental health: and to transform this new knowledge into future innovations.

    Precision Nutrition Innovation Arena (PNI) is an innovation environment that is part of the national food research center Plant-based Proteins for Health and Wellbeing (www.oru.se/pansweden), which is coordinated by Örebro University and consists of academic and private partners.

    Website: www.oru.se/pansweden/pni

    Coordinator: Örebro University (Amy Loutfi)

    Contact: Johnny Karlsson, pansweden@oru.se

    As objective and strategies for PNI are linked to those of PAN Sweden, there is a shared interest in applying a precision nutrition perspective to clarify the relationships between processing, structure, bioavailability, and digestion and fermentation of proteins with health effects in the form of intestinal, metabolic, and mental health: and to transform this new knowledge into future innovations.

    Precision Nutrition Innovation Arena (PNI) is an innovation environment that is part of the national food research center Plant-based Proteins for Health and Wellbeing (www.oru.se/pansweden), which is coordinated by Örebro University and consists of academic and private partners.

    Website: www.oru.se/pansweden/pni

    Coordinator: Örebro University (Amy Loutfi)

    Contact: Johnny Karlsson, pansweden@oru.se

  • in

    The innovation environment is an incubator for AI validation platforms. First, a platform for mammography screening will be developed, which will be able to function in regular healthcare operations from 2024. In addition, two other platforms will be prepared. Based on the pilots, the incubator will collect and disseminate general knowledge for AI validation, for the benefit of healthcare in general.

    The innovation environment is an incubator for AI validation platforms. First, a platform for mammography screening will be developed, which will be able to function in regular healthcare operations from 2024. In addition, two other platforms will be prepared. Based on the pilots, the incubator will collect and disseminate general knowledge for AI validation, for the benefit of healthcare in general.

    Imaging diagnostics, such as X-ray examinations and tissue samples, are a central part of healthcare. Artificial intelligence (AI) has shown great potential to be useful in imaging diagnostics. However, it has proven difficult for AI innovations to reach healthcare. A difficult challenge for healthcare providers is clinical validation, to check that the AI solution is patient-safe and efficient given the local conditions. Such AI validation is largely a capability that is still missing in healthcare, and this is what our innovation environment should address.

    Website: AIDA Medtech4Health - Incubator for Validation

    Coordinator: Sweden Medtech4Health AB

    Contact: Claes Lundström, AIDA & Linköping University, aida-director@medtech4health.se

    Imaging diagnostics, such as X-ray examinations and tissue samples, are a central part of healthcare. Artificial intelligence (AI) has shown great potential to be useful in imaging diagnostics. However, it has proven difficult for AI innovations to reach healthcare. A difficult challenge for healthcare providers is clinical validation, to check that the AI solution is patient-safe and efficient given the local conditions. Such AI validation is largely a capability that is still missing in healthcare, and this is what our innovation environment should address.

    Website: AIDA Medtech4Health - Incubator for Validation

    Coordinator: Sweden Medtech4Health AB

    Contact: Claes Lundström, AIDA & Linköping University, aida-director@medtech4health.se

  • in

    GeneNova is an innovation collaboration between academia and industry that aims to make Adeno-associated virus (AAV)-based gene therapy available to more patients and indications.

    GeneNova is an innovation collaboration between academia and industry that aims to make Adeno-associated virus (AAV)-based gene therapy available to more patients and indications.

    These therapies have incredible potential for curative treatment of a range of serious human diseases, but are currently only available to a fraction of patients in need. World-leading Swedish technology and service providers, pharmaceutical companies and universities have come together to develop strategies for the development and bioproduction of these advanced therapies. GeneNova's shared vision is to innovate and apply new technological solutions throughout the drug development process to enable the treatment of many more patients with these potentially transformative therapies.

    Website: www.genenova.org

    Coordinator: Kungliga Tekniska Högskolan (Johan Rockberg)

    Contact: info@genenova.org

    These therapies have incredible potential for curative treatment of a range of serious human diseases, but are currently only available to a fraction of patients in need. World-leading Swedish technology and service providers, pharmaceutical companies and universities have come together to develop strategies for the development and bioproduction of these advanced therapies. GeneNova's shared vision is to innovate and apply new technological solutions throughout the drug development process to enable the treatment of many more patients with these potentially transformative therapies.

    Website: www.genenova.org

    Coordinator: Kungliga Tekniska Högskolan (Johan Rockberg)

    Contact: info@genenova.org

  • in

    The project will provide improved preparedness for future pandemic outbreaks – opportunities and risks associated with large-scale disease surveillance in the population.

    The project will provide improved preparedness for future pandemic outbreaks – opportunities and risks associated with large-scale disease surveillance in the population.

    The project aims to design systems and methods to be able to follow the pandemic development in the population regarding

    • activity pattern
    • symptom state
    • test behavior (tests performed and test results)
    • occurrence of virus variants
    • healthcare contacts and hospitalizations
    • mortality
    • immunity
    • vaccination.

    All of this should be able to be used as a tool in combating pandemics and other health crises, e.g. to identify population groups or geographical areas in need of special efforts to reduce health risks. Furthermore, the aim is to facilitate research studies regarding, for example,

    • testing and vaccination pattern
    • spread of infection
    • vaccine effectiveness
    • side effects
    • sociodemographic studies
    • long-term follow-ups of those affected by the disease.

    Website:: PREPARE - Improved preparedness for future pandemic outbreaks - LUPOP

    Coordinator: Lunds Universitet (Matilda Almgren)

    Contact: jonas.bjork@med.lu.se

    The project aims to design systems and methods to be able to follow the pandemic development in the population regarding

    • activity pattern
    • symptom state
    • test behavior (tests performed and test results)
    • occurrence of virus variants
    • healthcare contacts and hospitalizations
    • mortality
    • immunity
    • vaccination.

    All of this should be able to be used as a tool in combating pandemics and other health crises, e.g. to identify population groups or geographical areas in need of special efforts to reduce health risks. Furthermore, the aim is to facilitate research studies regarding, for example,

    • testing and vaccination pattern
    • spread of infection
    • vaccine effectiveness
    • side effects
    • sociodemographic studies
    • long-term follow-ups of those affected by the disease.

    Website:: PREPARE - Improved preparedness for future pandemic outbreaks - LUPOP

    Coordinator: Lunds Universitet (Matilda Almgren)

    Contact: jonas.bjork@med.lu.se

  • in

    The objective of the PREDEM innovation environment is to prevent the development of dementia in people who are starting to have problems with memory or other cognitive functions.

    The objective of the PREDEM innovation environment is to prevent the development of dementia in people who are starting to have problems with memory or other cognitive functions.

    This will be done by more quickly introducing new ways to detect early onset dementia, make the correct diagnosis and offer treatment and preventive measures. We will evaluate and introduce new computer-based methods to find people who may be at risk of developing dementia, and test new laboratory tests that can show whether it is dementia or not.

    This information will be used to provide tailored information and recommendations regarding possible preventive measures and treatments. The information can also be used at a group level to determine how new medications and other treatments should best be used to provide good and equitable care for people at risk of dementia.

    Website: predem.ki.se

    Coordinator: Karolinska Institutetet (Linus Jönsson)

    Contact information: Linus.jonsson@ki.se

    This will be done by more quickly introducing new ways to detect early onset dementia, make the correct diagnosis and offer treatment and preventive measures. We will evaluate and introduce new computer-based methods to find people who may be at risk of developing dementia, and test new laboratory tests that can show whether it is dementia or not.

    This information will be used to provide tailored information and recommendations regarding possible preventive measures and treatments. The information can also be used at a group level to determine how new medications and other treatments should best be used to provide good and equitable care for people at risk of dementia.

    Website: predem.ki.se

    Coordinator: Karolinska Institutetet (Linus Jönsson)

    Contact information: Linus.jonsson@ki.se

  • in

    ASSET develops and evaluates new algorithms and computational structures based on artificial intelligence. The algorithms aim to provide methods for preventive, tailored treatments for type 1 diabetes and other autoimmune diseases.

    ASSET develops and evaluates new algorithms and computational structures based on artificial intelligence. The algorithms aim to provide methods for preventive, tailored treatments for type 1 diabetes and other autoimmune diseases.

    The project also works on technical and organizational issues surrounding the possibility of implementing screening and preventive treatment of people at high risk of developing type 1 diabetes and other autoimmune diseases in the Swedish healthcare system.

    Website: www.asset.healthcare

    Coordinator: Diamyd Medical AB

    Contact: Ulf Hannelius, ulf.hannelius@diamyd.com

    The project also works on technical and organizational issues surrounding the possibility of implementing screening and preventive treatment of people at high risk of developing type 1 diabetes and other autoimmune diseases in the Swedish healthcare system.

    Website: www.asset.healthcare

    Coordinator: Diamyd Medical AB

    Contact: Ulf Hannelius, ulf.hannelius@diamyd.com

  • in

    Indicell wants to provide new curative treatments for diseases for which there are rarely any treatments today or where the treatments aim to alleviate symptoms.

    Indicell wants to provide new curative treatments for diseases for which there are rarely any treatments today or where the treatments aim to alleviate symptoms.

    IndiCell has three main goals:

    • to develop iPS cell therapies for Parkinson's disease and Macular degeneration
    • to create a development pipeline for iPS cell therapies where knowledge can be applied to the development of stem cell therapies for other diseases such as diabetes, cancer and osteoarthritis.
    • that IndiCell and Sweden will become an important global player in stem cell therapies.

    IndiCell is a collaboration between academia (LU, KI, KTH), industry (BioLamina, AcouSort, MagicBioProcessing) and healthcare (SUS, Karolinska)

    Website: IndiCell - Innovation environment for individualized cell therapies

    Coordinator: Lunds Universitet (Anna Falk)

    Contact: Anna Falk: anna.falk@med.lu.se (scientific project manager) or Paulina.pettersson: paulina.pettersson@med.lu.se (administrative project manager)

    IndiCell has three main goals:

    • to develop iPS cell therapies for Parkinson's disease and Macular degeneration
    • to create a development pipeline for iPS cell therapies where knowledge can be applied to the development of stem cell therapies for other diseases such as diabetes, cancer and osteoarthritis.
    • that IndiCell and Sweden will become an important global player in stem cell therapies.

    IndiCell is a collaboration between academia (LU, KI, KTH), industry (BioLamina, AcouSort, MagicBioProcessing) and healthcare (SUS, Karolinska)

    Website: IndiCell - Innovation environment for individualized cell therapies

    Coordinator: Lunds Universitet (Anna Falk)

    Contact: Anna Falk: anna.falk@med.lu.se (scientific project manager) or Paulina.pettersson: paulina.pettersson@med.lu.se (administrative project manager)

  • in

    Increasing antibiotic resistance and shortages of antibiotics are some of the biggest challenges in healthcare today. Our objective is optimized and personalized antibiotic treatment for patients with acute infections.

    Increasing antibiotic resistance and shortages of antibiotics are some of the biggest challenges in healthcare today. Our objective is optimized and personalized antibiotic treatment for patients with acute infections.

    PLATINEA is an innovation environment consisting of actors from healthcare, universities, authorities and companies. In the 5-year project, we are working, among other things, to understand the reasons for backorders and develop proposals for how the availability of antibiotics can be improved. We are mapping knowledge gaps and conducting studies that provide new knowledge about how antibiotics should be used and dosed in the best way. In the long term, we hope that the project will lead to better care for patients with infections and reduced resistance development in society.

    Website: www.platinea.se

    Coordinator: Uppsala Universitet (Thomas Tängdén)

    Contact: Thomas Tängdén, thomas.tangden@medsci.uu.se

    PLATINEA is an innovation environment consisting of actors from healthcare, universities, authorities and companies. In the 5-year project, we are working, among other things, to understand the reasons for backorders and develop proposals for how the availability of antibiotics can be improved. We are mapping knowledge gaps and conducting studies that provide new knowledge about how antibiotics should be used and dosed in the best way. In the long term, we hope that the project will lead to better care for patients with infections and reduced resistance development in society.

    Website: www.platinea.se

    Coordinator: Uppsala Universitet (Thomas Tängdén)

    Contact: Thomas Tängdén, thomas.tangden@medsci.uu.se

  • in

    The innovation environment is a test bed for clinical studies that facilitate the introduction of more accurate prevention and treatment in cancer care.

    The innovation environment is a test bed for clinical studies that facilitate the introduction of more accurate prevention and treatment in cancer care.

    The overall objective of the innovation environment is to contribute to increased access to and participation in clinical studies, increased precision in prevention and diagnostics, more effective medical treatments and techniques, increased use of existing infrastructure and increased internationalisation. The innovation environment will develop a model to stimulate the development of national precision medicine studies and a model for a national MTB portal (Molecular Tumour Board). The model development also includes support for data analysis and data sharing, health economic tools, payment models, educational initiatives and adaptation of guidelines and other knowledge support in cancer care for cohesive patient journeys.

    The initiators are Nollvision cancer, Genomic Medicine Sweden, SciLifeLab and the research consortium MEGALiT.

    Website: Testbed Sweden Precision Health Cancer

    Coordinator:Stockholm School of Economics (Ebba Hult)

    Contact: Ebba Hallersjö Hult ebba.hallersjo.hult@hhs.se or Anders Edsjö anders.edsjo@skane.se

    The overall objective of the innovation environment is to contribute to increased access to and participation in clinical studies, increased precision in prevention and diagnostics, more effective medical treatments and techniques, increased use of existing infrastructure and increased internationalisation. The innovation environment will develop a model to stimulate the development of national precision medicine studies and a model for a national MTB portal (Molecular Tumour Board). The model development also includes support for data analysis and data sharing, health economic tools, payment models, educational initiatives and adaptation of guidelines and other knowledge support in cancer care for cohesive patient journeys.

    The initiators are Nollvision cancer, Genomic Medicine Sweden, SciLifeLab and the research consortium MEGALiT.

    Website: Testbed Sweden Precision Health Cancer

    Coordinator:Stockholm School of Economics (Ebba Hult)

    Contact: Ebba Hallersjö Hult ebba.hallersjo.hult@hhs.se or Anders Edsjö anders.edsjo@skane.se

  • in

    SwAIPP's objective is to establish a leading national and international innovation environment for research and development of AI-based precision pathology, as well as to implement AI-based pathology for cancer diagnostics in healthcare on a large-scale level.

    SwAIPP's objective is to establish a leading national and international innovation environment for research and development of AI-based precision pathology, as well as to implement AI-based pathology for cancer diagnostics in healthcare on a large-scale level.

    The aim is to accelerate the development and availability of new AI-based diagnostic solutions that enable improved diagnostic accuracy as well as the extraction of new clinically relevant information through image analysis of tissue samples. The methods developed and implemented within SwAIPP enable rapid diagnostics at a fraction of the cost of, for example, molecular diagnostics. This means that more patients will be able to benefit from improved accuracy and shorter time to diagnosis.

    The innovation environment is a cross-sector collaboration between Karolinska Institutet, Stratipath AB, Microsoft Sverige AB, Roche Diagnostics AB, Philips AB, the Swedish Breast Cancer Association, Prevas AB (MEDQURE), Helseplan AB and the regions of Kalmar, Västmanland and Skåne.

    Website: https://swaipp.org

    Coordinator: Mattias Rantalainen, Lecturer at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet

    Contact: Coordinator Mattias Rantalainen ( mattias.rantalainen@ki.se, tel 08- 524 824 65) or administrator Anna Berglund ( anna.berglund@ki.se, tel 08-524 822 16)

    The aim is to accelerate the development and availability of new AI-based diagnostic solutions that enable improved diagnostic accuracy as well as the extraction of new clinically relevant information through image analysis of tissue samples. The methods developed and implemented within SwAIPP enable rapid diagnostics at a fraction of the cost of, for example, molecular diagnostics. This means that more patients will be able to benefit from improved accuracy and shorter time to diagnosis.

    The innovation environment is a cross-sector collaboration between Karolinska Institutet, Stratipath AB, Microsoft Sverige AB, Roche Diagnostics AB, Philips AB, the Swedish Breast Cancer Association, Prevas AB (MEDQURE), Helseplan AB and the regions of Kalmar, Västmanland and Skåne.

    Website: https://swaipp.org

    Coordinator: Mattias Rantalainen, Lecturer at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet

    Contact: Coordinator Mattias Rantalainen ( mattias.rantalainen@ki.se, tel 08- 524 824 65) or administrator Anna Berglund ( anna.berglund@ki.se, tel 08-524 822 16)

Read the call for proposals that form the basis for the environments

Funding

Innovation milieus in precision Health 2021

Read more about precision health

News

Innovation environments for more accurate solutions in health

Last updated 25 June 2025